by Teresa Carvalho MSc
The pivotal Phase 3 VIITAL clinical trial of EB-101, Abeona Therapeutics’ experimental cell therapy for wound healing in people with recessive dystrophic epidermolysis bullosa (RDEB), has met its enrollment target.
The company also announced that top-line results from the VIITAL trial (NCT04227106) are expected in the in third quarter of this year … read more
If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.